Cyclerion Therapeutics
CYCN
61 hedge funds and large institutions have $75.8M invested in Cyclerion Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 14 closing their positions.
249% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $456K
0.19% less ownership
Funds ownership: 3.05% → 2.85% (-0.19%)
9% less funds holding
Funds holding: 67 → 61 (-6)
21% less capital invested
Capital invested by funds: $96M → $75.8M (-$20.2M)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.22M |
| 2 |
Two Sigma Advisers
New York
|
+$1.05M |
| 3 |
Two Sigma Investments
New York
|
+$775K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$380K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$695K |
| 2 |
E
Ergoteles
New York
|
-$375K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$373K |
| 4 |
D.E. Shaw & Co
New York
|
-$336K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$332K |
CYCN Hedge Fund Activity: Q3 2021 in Review
61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2021, worth a combined $75.8M — down 21% from $96M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CYCN and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 13 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $1.22M. The largest seller was Renaissance Technologies, cutting an estimated $695K.
- 61 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2021, down from 67 in Q2 2021.
- Funds reported $75.8M of Cyclerion Therapeutics stock for Q3 2021, down 21% quarter-over-quarter.
- 10 funds opened new Cyclerion Therapeutics positions in Q3 2021 and 14 closed out, a net change of -4 holders.
- The largest Cyclerion Therapeutics buyer in Q3 2021 was Eversept Partners, an estimated $1.22M added.
- The largest Cyclerion Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $695K sold.
Based on aggregated 13F filings for Q3 2021.